X

Trial Profile

Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary)
Indications Embolism and thrombosis; Stroke
Focus Therapeutic Use
Acronyms ALVO trial

Most Recent Events

21 Feb 2020 Results estimating the cumulative incidences of bleeding and ischemic events as well as all-cause mortality in patients on apixaban for nonvalvular atrial fibrillation and and acute large vessel occlusion, presented at the International Stroke Conference 2020
03 Aug 2019 Status changed from recruiting to completed.
22 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com